Roche: EC approves leukaemia treatment
(CercleFinance.com) - Roche today announced that the European Commission has approved Venclyxto (venetoclax) in combination with Gazyvaro (obinutuzumab) for the treatment of adult patients with untreated chronic lymphocytic leukaemia (CLL).
The approval is based on the results of the primary analysis of the Phase III CLL14 study, which evaluated the 12-month combination. "Data showed that a fixed duration of treatment with Venclyxto plus Gazyvaro reduced the risk of disease progression or death by 65% compared to a current standard-of-care," the group said.
"The data showed that a fixed duration of treatment with Venclyxto plus Gazyvaro reduced the risk of disease progression or death by 65% compared to a current standard of care," said the group.
Venclyxto plus Gazyvaro is the first fixed-duration, chemotherapy-free treatment option that has been shown to help patients with untreated chronic lymphocytic leukaemia live longer without their disease progressing,” said Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The approval is based on the results of the primary analysis of the Phase III CLL14 study, which evaluated the 12-month combination. "Data showed that a fixed duration of treatment with Venclyxto plus Gazyvaro reduced the risk of disease progression or death by 65% compared to a current standard-of-care," the group said.
"The data showed that a fixed duration of treatment with Venclyxto plus Gazyvaro reduced the risk of disease progression or death by 65% compared to a current standard of care," said the group.
Venclyxto plus Gazyvaro is the first fixed-duration, chemotherapy-free treatment option that has been shown to help patients with untreated chronic lymphocytic leukaemia live longer without their disease progressing,” said Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development.
Copyright (c) 2020 CercleFinance.com. All rights reserved.